Comorbidities Predict Inferior Survival in Patients receiving Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma: A Multicenter Analysis

Chimeric Antigen Receptor (CAR) T-cell therapy is approved for treatment of relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Here, we evaluate whether comorbidities, calculated by the Cumulative Illness Rating Scale (CIRS), predict survival for these patients.

Source: Biology of Blood and Marrow Transplantation - September 27, 2020 Category: Hematology Authors: Adam S. Kittai, Ying Huang, Max Gordon, Nathan Denlinger, Agrima Mian, Lindsey Fitzgerald, Jennifer Bishop, Sarah Nagle, Deborah M. Stephens, Samantha JaglowskiMPH, Brian Hill, Alexey V. Danilov Source Type: research